Zimmer Biomet Holdings (ZBH) Company Overview

Zimmer Biomet gains advantages from its varied range of products beyond just orthopedics, as well as its smart investments in promising, fast-growing areas.

While the revenue and earnings per share (EPS) for Zimmer (ZBH) provide insight into its performance for the quarter ending December 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.

Zimmer Biomet (ZBH) reported quarterly earnings of $2.31 per share, which is higher than the Zacks Consensus Estimate of $2.30 per share. This is an increase compared to earnings of $2.20 per share from the same period last year.

In the fourth quarter, net sales reached $2.023 billion, showing a 4.3% increase, or 4.9% when adjusted for constant currency. The diluted earnings per share for the quarter were $1.20, while the adjusted figure was $2.31. For the entire year, net sales totaled $7.679 billion, up by 3.8% or 4.8% on a constant currency basis, with diluted earnings per share at $4.43 and adjusted earnings at $8.00.

Instead of just focusing on Wall Street's predictions for Zimmer (ZBH), it's important to examine some of its key metrics to better understand how the company might perform in the quarter ending December 2024. This deeper analysis can provide valuable insights into its potential success.

ZBH's Hips division is likely to have experienced growth due to its range of navigation solutions for direct anterior stems and surgical impactors.

Zimmer Biomet is making strong efforts to grow its Knee business, and the musculoskeletal market seems to be stabilizing gradually, which looks encouraging.

Zimmer Biomet Holdings (ZBH) is broadening its range of products and enhancing its cash flow, setting itself up for lasting profits and financial stability. Compared to its competitors, ZBH is undervalued and has great growth potential due to its focus on innovation, acquisitions, and better operational efficiency. The company's emphasis on high-growth markets and improving profit measures suggests a positive future, even though it has not performed well in the past.

Zimmer Biomet is experiencing significant growth in its market share for reconstructive knees and hips in important regions, even with the difficulties in the overall economy.